Page 220

11. Bouaboula M, Perrachon S, Milligan L, Canat X, Rinaldi-Carmona M, Portier MB, Calandra B, Pecceu F, Lupker J, Maffrand JP, Le Fur G, Casellas P. 1997. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. Journal of Biological Chemistry 272:2233022339.

12. Calhoun, SR, Galloway GP, Smith DE. 1998. Abuse potential of dronabinol (Marinol). Journal of Psychoactive Drugs 30:187-196.

13. Cooper RM. 1980. Therapeutic use of marijuana and heroin: The legal framework. Food Drug Cosmetic Law Journal 35:68-82.

14. DEA (Drug Enforcement Administration). 1992. Marijuana scheduling petition; denial of petition; remand. Federal Register 57:10499-10508.

15. DEA. 1998. Drugs of abuse [WWW document].URL http://www.usdoj.gov/dea/ pubs/abuse/contents.htm (accessed September 1998).

16. DEA. 1996. The National Narcotics Intelligence Consumers Committee (NNICC) report [WWW document].URL www.usdoj.gov/dea/pubs/intel/nnicc97.htm  (accessed September 1998).

17. DEA. 1998b. Rescheduling of synthetic dronabinol from Schedule II to Schedule III. Federal Register 63:59751-59753.

18. DiMasi JA, Brown JS, Lasagna L. 1996. An analysis of regulatory review times of supplemental indications for already-approved drugs: 1989-1994. Drug Information Journal 30:315-337.

19. DiMasi JA, Hanson RW, Grabowski HG, Lasagna L. 1995. Research and development costs for new drugs by therapeutic category: A study of the U.S. pharmaceutical industry. Pharmaco Economics 7:152-169.

20. FDA (Food and Drug Administration). 1990. From Test Tube to Patient: New Drug Development in the United States. Rockville, MD: U.S. Department of Health and Human Services.

21. FDA. 1997b. Draft Guidelines for Research Involving the Abuse Liability Assessment of New Drugs. Rockville, MD: U.S. Department of Health and Human Services. Division of Anesthetic, Critical Care and Addiction Drug Products.

22. FDA. 1997a. Center for Drug Evaluation and Research Fact Book [WWW document]. URL http://www.fda.gov/cder/homepage (accessed September 1998).

23. FDA. 1998a. Center for Drug Evaluation and Research Handbook [WWW document]. URL http://www.fda/cder/handbook.htm  (accessed September 1998).

24a. FDA. 1998b. FDA proposes rules for dissemination information on off label uses (press release, June 5). Washington, DC: U.S. Department of Health and Human Services.

24. FDA. 1998c. Guidance for industry: Providing clinical evidence of effectiveness for human drugs and biological products. Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. May 1998 [WWW document].URL http://www.fda.gov/cder/guidance/1397fnl.pdf (accessed September 1998).

25. FDA. 1998d. Office of Orphan Products Development Program Overview [WWW document].URL http://www.fda.gov/orphan/DESIGNAT/recent.htm  (accessed October 14, 1998).

26. Felder CC, Glass M. 1998. Cannabinoid receptors and their endogenous agonists. Annual Reviews of Pharmacology and Toxicology 38:179-200.

27. Glain SJ. 1998. 1. Wall Street Journal.

28. Gollin MA. 1994. Patenting recipes from nature's kitchen: How can a naturally occurring chemical like taxol be patented? Biotechnology (NY) 12:406-407.

Front Matter (R1-R18)

Executive Summary (1-12)

1 Introduction (13-32)

2 Cannabinoids and Animal Physiology (33-82)

3 First, Do No Harm: Consequences of Marijuana Use and Abuse (83-136)

4 The Medical Value of Marijuana and Related Substances (137-192)

5 Development of Cannabinoid Drugs (193-222)

Appendix A Individuals and Organizations That Spoke or Wrote to the Institute of Medicine About Marijuana and Medicine (223-231)

Appendix B Workshop Agendas (232-239)

Appendix C Scheduling Definitions (240-241)

Appendix D Statement of Task (242-243)

Appendix E Recommendations Made in Recent Reports on the Medical Use of Marijuana (244-255)

Appendix F Rescheduling Criteria (256-258)

Index (259-267)